Results for tag: "Alpha1 Proteinase Inhibitor"

The Alpha1 Proteinase Inhibitor market is a subset of the larger Respiratory Drugs market. Alpha1 Proteinase Inhibitors are used to treat Alpha1 Antitrypsin Deficiency (AATD), a genetic disorder that can cause lung and liver damage. These drugs are designed to replace the missing or deficient Alpha1 Antitrypsin protein in the body, helping to reduce the risk of lung and liver damage. Alpha1 Proteinase Inhibitors are typically administered through an intravenous infusion, and are used to treat both adults and children. The Alpha1 Proteinase Inhibitor market is highly competitive, with several major players in the space. Companies such as Grifols, CSL Behring, and Kamada are all major players in the Alpha1 Proteinase Inhibitor market. Other companies such as Chiesi, Baxter, and Octapharma also have a presence in the market. Show Less Read more